US Patent

US10272079 — NHE3-binding compounds and methods for inhibiting phosphate transport

Method of Use · Assigned to Ardelyx Inc · Expires 2034-04-10 · 8y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects NHE3-binding and/or NHE3-modulating agents that inhibit phosphate transport in the gastrointestinal tract and kidneys.

USPTO Abstract

Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.

Drugs covered by this patent

tenapanor-hydrochloride (TENAPANOR HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-381`	—	tenapanor-hydrochloride
`U-3736`	—	tenapanor-hydrochloride
`U-3736`	—	tenapanor-hydrochloride

Patent Metadata

Patent number: US10272079
Jurisdiction: US
Classification: Method of Use
Expires: 2034-04-10
Drug substance claim: No
Drug product claim: No
Assignee: Ardelyx Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.